Robert H. Smith School of Business
The Motley Fool

Market Foolery Featured Podcasts

  • GDP & Keurig Gets Burned
    3rd-quarter GDP grows 5%. Keurig Green Mountain recalls 7 million machines due to reports of burn-related injuries.  Plus we dip into the Fool Mailbag and discuss the state of hedge funds.
  • Year in Review - Energy
    We look back on the year in the energy industry, including the top energy stocks of 2014, a CEO of note, and a potential IPO for 2015.
  • MarketFoolery: 12.18.2014
    Rite Aid soars. America runs away from Dunkin’ Brands.  And Oracle closes in on an all-time high. Plus we discuss investing opportunities in Cuba.
Capital Business
Posted at 11:13 AM ET, 07/16/2012

GlaxoSmithKline buys Human Genome Sciences for $3.6B


Human Genome Sciences' headquarters in Rockville. (Jeffrey MacMillan - Capital Business)
British drugmaker GlaxoSmithKline has agreed to pay $3.6 billion for Rockville-based Human Genome Sciences after a months-long acquisition dispute over the company’s true value.

Glaxo has extended multiple buyout offers since April to both the HGS board of directors and its shareholders that valued the company at $2.6 billion, or $13 per share, but the company repeatedly rejected them as too low.

This latest agreement will fetch $14.25 per share in cash for HGS, a transaction value worth about $3.6 billion on an equity basis, or approximately $3 billion net of cash and debt, the companies said.

The deal brings an end to what had become an increasingly heated battle for control of the company.

Glaxo had attempted to bypass the board and purchase stock directly from investors. HGS then thwarted that effort with a poison pill, but gained a lawsuit from some disgruntled shareholders in response.

The two firms are development and marketing partners on several drugs, including Benlysta, which was approved by the Food and Drug Administration last year to treat systemic lupus.

By  |  11:13 AM ET, 07/16/2012

 
Read what others are saying
     

    © 2011 The Washington Post Company